CBER Gene Therapy Office To Be Established By Oct. 1
Executive Summary
CBER's Office of Cells, Tissues & Gene Therapy will address the "evolution" of scientific and regulatory issues, FDA Center for Biologics Evaluation & Research Director Kathryn Zoon, PhD, said May 29
You may also be interested in...
CBER Gene Therapy Office May Be Isolated In FDA Reorganization Plan
FDA's proposed transfer of therapeutic biologic reviews to the drug center could negatively affect the newly created CBER Office of Cellular, Tissue & Gene Therapies, Acting Director Phillip Noguchi, MD, said
CBER Gene Therapy Office May Be Isolated In FDA Reorganization Plan
FDA's proposed transfer of therapeutic biologic reviews to the drug center could negatively affect the newly created CBER Office of Cellular, Tissue & Gene Therapies, Acting Director Phillip Noguchi, MD, said
CBER Cellular & Gene Therapies Division’s Acting Director Is Raj Puri
Center for Biologics Evaluation & Research researcher Raj Puri, MD/PhD, will be the acting director of the relocated Division of Cellular & Gene Therapies under CBER's new Office of Cellular, Tissue & Gene Therapies